Our data indicate that cblb targeting in T cells alone is not sufficient to counteract cancer-associated immune suppression, but that reactivation of the engineered T cells by a DC vaccine induces a profound anti-tumor immune response in non-TCR-transgenic mice (74). Here, CBLB is linked to neoplasm.